Breast Imaging Market size was valued at USD 6.4 billion in 2026 and is anticipated to grow at a 9.22% CAGR from 2027 to 2036, surpassing USD 15.46 billion by 2036. The industry revenue for 2027 is assessed at USD 6.9 billion.
The increasing burden of breast cancer is strengthening the need for timely detection, diagnosis, and monitoring across healthcare systems. The breast imaging market is supported by this clinical demand as healthcare providers rely on advanced imaging procedures to identify abnormalities and characterize breast tissue with greater diagnostic detail. Growing emphasis on earlier identification of suspicious lesions is also increasing the role of imaging throughout the diagnostic pathway.
The integration of artificial intelligence into breast imaging is helping radiologists process complex image data and identify potentially suspicious findings more efficiently. AI technologies are supporting the breast imaging market by assisting with image interpretation, prioritization of cases, and workflow management, while helping reduce repetitive tasks within diagnostic environments. These capabilities can complement radiologist expertise by providing additional analytical support during image assessment.
The expansion of organized breast cancer screening programs is increasing the need for imaging systems capable of supporting large patient volumes and varied diagnostic requirements. Within the breast imaging market, hybrid technologies can combine complementary imaging capabilities to provide more comprehensive assessment of breast abnormalities and tissue characteristics. Broader screening access is also encouraging healthcare facilities to strengthen imaging infrastructure and integrate advanced modalities into routine diagnostic pathways.
| Growth Driver Assessment Framework | |||||
| Growth Driver | Impact On CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising global breast cancer incidence accelerating demand for advanced diagnostic imaging procedures | 2.00% | High | North America, Europe | High | Near Term |
| AI-assisted imaging platforms improving diagnostic precision and radiology workflow efficiency | 1.80% | Moderate | North America, Europe, Asia Pacific | High | Mid Term |
| Expanding population-based screening programs increasing deployment of hybrid breast imaging technologies | 1.40% | High | Asia Pacific, Latin America, Middle East & Africa | Emerging | Long Term |
North America dominated the breast imaging market in 2026, supported by established healthcare infrastructure, widespread access to advanced diagnostic technologies, and strong emphasis on early detection and preventive breast health. The region benefits from mature screening programs and a high level of clinical adoption of sophisticated imaging modalities, enabling healthcare providers to identify abnormalities and support timely diagnostic decisions. Continued technological development is also encouraging the integration of more advanced imaging capabilities into clinical workflows, while increasing awareness of breast cancer screening contributes to sustained demand for diagnostic services. Favorable reimbursement structures and healthcare investments further support the adoption and replacement of imaging equipment. In addition, established clinical expertise and the presence of specialized diagnostic facilities strengthen the region’s ability to implement advanced breast imaging technologies, maintaining its leading market position.
Asia Pacific is emerging as the fastest-growing regional market, driven by expanding healthcare infrastructure, increasing awareness of breast cancer screening, and improving access to diagnostic services. Growing healthcare expenditure and investments in medical facilities are enabling more hospitals and diagnostic centers to introduce modern imaging technologies, particularly in developing healthcare markets. Rising urban populations and greater awareness of preventive healthcare are also encouraging more women to seek screening and diagnostic evaluation. At the same time, efforts to improve early detection and expand access to specialized healthcare services are creating additional opportunities for breast imaging technologies. As healthcare systems continue to modernize and diagnostic capacity expands, the region is positioned for strong adoption of advanced breast imaging solutions.
The U.S. breast imaging market prioritizes advanced imaging technologies that improve diagnostic accuracy and workflow efficiency across screening programs. Healthcare providers in the U.S. continue integrating digital platforms and artificial intelligence to support earlier detection and more consistent clinical decision-making.
Japan emphasizes breast imaging technologies capable of delivering detailed visualization for accurate clinical assessment. Japanese healthcare providers continue adopting advanced digital imaging solutions that improve examination quality while supporting efficient diagnostic workflows in specialized care facilities.
South Korea continues strengthening breast imaging capabilities through investments in digital diagnostic equipment and integrated healthcare technologies. Medical providers in South Korea focus on improving screening accessibility and workflow efficiency while supporting timely and accurate breast cancer evaluation.
Germany focuses on breast imaging systems that enhance image quality and support standardized diagnostic pathways. German healthcare institutions invest in advanced imaging equipment that improves clinical reliability while supporting efficient patient management across screening and diagnostic settings.
France supports breast imaging through structured screening initiatives and continuous modernization of diagnostic equipment. French healthcare providers emphasize reliable imaging technologies that improve early detection while maintaining consistent clinical quality across healthcare facilities.
Italy is modernizing breast imaging services by expanding access to digital diagnostic technologies and improving imaging workflows. Healthcare institutions in Italy prioritize equipment upgrades that enhance diagnostic confidence and support efficient patient evaluation within established screening programs.
Hospitals represented the largest end-use segment of the breast imaging market in 2026, reflecting their central role in comprehensive breast health services. Hospitals typically provide integrated diagnostic, surgical, oncology, and follow-up care, allowing breast imaging to be incorporated into broader patient management pathways. The availability of specialized medical personnel and advanced diagnostic infrastructure further supports extensive utilization in hospital settings. Increasing emphasis on early detection and coordinated cancer care continues to reinforce the importance of hospitals as major users of breast imaging technologies.
Diagnostic centers are expected to be the fastest-growing end-use segment, supported by increasing demand for accessible and specialized diagnostic services. Dedicated imaging facilities can offer streamlined scheduling, focused breast screening capabilities, and efficient diagnostic workflows, making them attractive for patients and healthcare providers seeking convenient imaging services. Growing awareness of routine breast screening and the broader shift toward decentralized diagnostic care are creating additional opportunities for specialized centers. Investments in modern imaging infrastructure and improvements in diagnostic efficiency are also supporting their expanding role.
Mammography led the technology segment of the breast imaging market in 2026 and is also expected to be the fastest-growing technology. Its strong position is supported by its established role in breast cancer screening and its ability to identify abnormalities that may require further clinical evaluation. Continued emphasis on early detection and routine screening programs sustains demand for mammography across healthcare settings. Technological improvements, including enhanced image quality and digital capabilities, are helping strengthen diagnostic workflows while supporting more efficient screening and follow-up procedures. The continuing focus on earlier identification of breast abnormalities is expected to maintain strong momentum for mammography.
| Report Segmentation | |||
| Segment | Sub-Segment | Largest Segment | Fastest Growing Segment |
|---|---|---|---|
| End-use | Hospitals, Diagnostic Centers, Others | Hospitals | Diagnostic Centers |
| Technology | Mammography, Ultrasound, MRI, Others | Mammography | Mammography |
1. GE HealthCare Technologies Inc. (GE Healthcare) (United States)
2. Hologic Inc. (United States)
3. Philips Healthcare (Netherlands)
4. Siemens Healthineers AG (Germany)
5. Fujifilm Holdings Corporation (Japan)
6. Canon Medical Systems Corporation (Japan)
7. Aurora Imaging Technology Inc. (United States)
8. Dilon Technologies Inc. (United States)
9. SonoCine Inc. (United States)
10. Mindray Medical International Limited (China)
The breast imaging market is evolving with advancements in diagnostic imaging precision and early detection capabilities. Enhanced imaging modalities are improving clinical accuracy and patient outcomes. Continuous research activity is supporting development of more efficient imaging systems, while growing demand for early diagnosis solutions is driving wider adoption of advanced screening technologies across healthcare systems.
| Company Name | Date | Key Development |
|---|---|---|
| Siemens Healthineers | Oct-24 | Siemens Healthineers received FDA approval for a next-generation 3D mammography system. Featuring advanced tomosynthesis capabilities and improved workflow integration, the platform is designed to increase diagnostic accuracy and throughput, reinforcing the company's competitive standing in the high-precision breast screening market. |
| Owkin | Oct-24 | Owkin partnered with AstraZeneca to develop an AI tool capable of identifying gBRCA mutations from digitized pathology slides. This innovation aims to transform breast cancer risk stratification by enabling earlier identification of eligible patients for genetic testing and precision oncology therapies, demonstrating the expansion of AI into diagnostic molecular profiling. |
| Hologic | Jan-25 | Hologic completed the $350 million acquisition of Gynesonics, integrating the Sonata System into its women’s health portfolio. The move expands Hologic’s imaging and interventional capabilities for uterine diagnostics and treatment, strengthening its overall ecosystem of integrated women’s health technologies beyond core breast-specific platforms. |
| DeepHealth | Feb-25 | DeepHealth announced the European launch of its Diagnostic Suite, incorporating a workflow-optimized PACS system and its SmartMammo AI-driven detection platform. The rollout aims to consolidate clinical decision support tools into a unified radiology workspace, facilitating the adoption of automated mammography diagnostics in international clinical settings. |
| Koios Medical | Mar-25 | Koios Medical partnered with iCAD to provide a multi-modality AI breast cancer detection suite. By integrating SmartUltrasound with ProFound AI for mammography, the collaboration enables radiologists to leverage combined decision-support data across screening and diagnostic workflows, improving overall cancer detection accuracy through cross-platform software synergy. |
| Clairity, Inc. | Jun-25 | Clairity, Inc. received FDA De Novo authorization for Clairity Breast, an AI platform that predicts a woman's five-year breast cancer risk using routine mammograms. This regulatory breakthrough establishes a new clinical paradigm for personalized breast cancer screening, shifting focus from pure detection toward proactive, risk-based preventative care. |
| RadNet | Jul-25 | RadNet finalized the acquisition of iCAD, merging advanced AI detection tools with its nationwide imaging network through the DeepHealth platform. The vertical integration of hardware and software aims to drive significant improvements in diagnostic efficiency and screening accuracy, setting a benchmark for AI-driven clinical delivery at scale. |
| Radiology Partners | Oct-25 | Radiology Partners launched "Mammo Enhance Heart," an AI-enabled program utilizing screening mammograms to identify breast arterial calcifications. This service bridges the gap between imaging centers and cardiology networks, diversifying the clinical utility of breast imaging data into cardiovascular risk assessment and preventative care management. |
| iSono Health | Jan-26 | iSono Health commercially launched ATUSA, an FDA-cleared automated 3D breast ultrasound platform. By utilizing wearable technology to reduce dependency on traditional sonographer staffing and clinical infrastructure, the system addresses critical labor shortages and improves accessibility to high-quality breast imaging in outpatient environments. |
| Solis Mammography | May-26 | Solis Mammography expanded its clinical footprint with four new centers in the U.S., supported by TowerBrook Capital. The expansion underscores a strategic focus on scaling outpatient imaging capacity and centralizing high-demand diagnostic services, reflecting continued investor confidence in the commercial consolidation of women’s health screening networks. |